SPY313.78-3.27 -1.03%
DIA259.04-3.96 -1.51%
IXIC10,343.89-89.76 -0.86%

Achieve Announces Successful Results From Investigator-Initiated RAUORA Head-To-Head Non-Inferiority Clinical Trial Comparing Cytisinicline And Chantix As A Treatment To Quit Smoking

Cytisinicline demonstrated quit rates at least as effective as varenicline Participants on cytisinicline experienced significantly fewer side effects than those on varenicline SEATTLE and VANCOUVER, BC, June 29,

Benzinga · -

Cytisinicline demonstrated quit rates at least as effective as varenicline

Participants on cytisinicline experienced significantly fewer side effects than those on varenicline

SEATTLE and VANCOUVER, BC, June 29, 2020 /CNW/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the successful topline results from the New Zealand RAUORA Phase 3 non-inferiority clinical trial comparing cytisinicline to varenicline (Chantix®) in Māori (indigenous New Zealanders) and whānau (family) of Māori. The study was led by Dr. Natalie Walker, Associate Professor at the University of Auckland, and was funded by the Health Research Council of New Zealand.